



## The Pathway of Nitrate, Nitrite, and Nitric Oxide: Possible Function in Reducing Oxidative Stress in Hypertensive Conditions Associated with Pregnancy

Priscila Jose\*

Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of São Paulo—USP, Ribeirão Preto 14049-900, SP, Brazil

### INTRODUCTION

Hypertensive disorders during pregnancy, such as preeclampsia, are major causes of maternal and fetal morbidity and mortality worldwide. Nitric oxide is a key regulator of vascular function and blood pressure, and its bioavailability is reduced in hypertensive conditions. This article explores the role of the nitrate-nitrite-NO pathway in reducing oxidative stress and improving vascular function, potentially offering novel therapeutic avenues for managing hypertensive disorders in pregnancy. Hypertensive disorders during pregnancy, including preeclampsia and gestational hypertension, are significant contributors to maternal and perinatal morbidity and mortality. Preeclampsia, in particular, is characterized by new-onset hypertension and proteinuria after 20 weeks of gestation and can lead to severe complications, such as eclampsia, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), and adverse fetal outcomes. Despite extensive research, the exact pathophysiology of preeclampsia remains unclear, and effective treatments are limited to delivery of the placenta, which often necessitates preterm birth [1].

### DESCRIPTION

Nitric oxide is a key signaling molecule involved in the regulation of vascular tone, platelet aggregation, leukocyte adhesion, and smooth muscle cell proliferation. It is synthesized from the amino acid L-arginine by the enzyme nitric oxide synthase and exerts its effects by activating soluble guanylate cyclase and increasing cyclic guanosine monophosphate levels in target cells. In the vasculature, NO promotes vasodilation by relaxing

vascular smooth muscle cells, thereby reducing peripheral resistance and blood pressure [2].

In addition to endogenous NO production, the nitrate-nitrite-NO pathway represents an alternative source of NO in the body. Dietary nitrate is primarily derived from green leafy vegetables and is converted to nitrite by commensal bacteria in the oral cavity. Nitrite can then be further reduced to NO in a process facilitated by various enzymatic and non-enzymatic pathways, particularly under conditions of hypoxia or acidosis. This pathway is of particular interest in conditions where NO bioavailability is compromised, such as in hypertensive disorders associated with pregnancy [3].

During pregnancy, NO plays a crucial role in maintaining uteroplacental perfusion and fetal development. It is involved in the modulation of vascular tone in the uterine and systemic circulations, as well as in the regulation of trophoblast invasion and spiral artery remodeling. Dysregulation of NO signaling has been implicated in the pathophysiology of preeclampsia, where reduced NO bioavailability contributes to endothelial dysfunction, vasoconstriction, and oxidative stress [4].

Oxidative stress, characterized by an imbalance between the production of reactive oxygen species and antioxidant defenses, is a hallmark feature of hypertensive disorders in pregnancy. ROS can react with NO to form peroxynitrite a highly reactive oxidant that can further exacerbate endothelial dysfunction and tissue damage. By enhancing NO bioavailability, either through increased endogenous production or exogenous supplementation with nitrate or nitrite, it may be possible to mitigate oxidative stress and improve vascular function in hypertensive conditions associated with pregnancy [5].

<b>Received:</b>	02-March-24	<b>Manuscript No:</b>	ipgocr-24-19962
<b>Editor assigned:</b>	04-March-24	<b>PreQC No:</b>	ipgocr-24-19962 (PQ)
<b>Reviewed:</b>	16-March-24	<b>QC No:</b>	ipgocr-24-19962 (Q)
<b>Revised:</b>	22-March-24	<b>Manuscript No:</b>	ipgocr-24-19962 (R)
<b>Published:</b>	29-March-24	<b>DOI:</b>	10.36648/2471-8165.10.02.11

**Corresponding author:** Priscila Jose, Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of São Paulo—USP, Ribeirão Preto 14049-900, SP, Brazil; E-mail: josep@cicams.ac.cn

**Citation:** Jose P (2024) The Pathway of Nitrate, Nitrite, and Nitric Oxide: Possible Function in Reducing Oxidative Stress in Hypertensive Conditions Associated with Pregnancy. *Gynecol Obstet Case Rep.* Vol.10 No.2:11.

**Copyright:** © Jose P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

## CONCLUSION

Several studies have investigated the effects of dietary nitrate and nitrite supplementation in animal models and humans with various cardiovascular conditions. In pregnant rats, dietary nitrate supplementation has been shown to improve uterine perfusion and fetal growth in a model of placental ischemia-induced hypertension. Similarly, in humans, dietary nitrate supplementation has been associated with reductions in blood pressure and improvements in endothelial function. However, further research is needed to elucidate the specific effects of nitrate and nitrite supplementation in hypertensive disorders of pregnancy. The nitrate-nitrite-NO pathway represents a novel and potentially important mechanism for reducing oxidative stress and improving vascular function in hypertensive disorders associated with pregnancy. By enhancing NO bioavailability, either through dietary interventions or pharmacological agents, it may be possible to mitigate the severity of these conditions and improve maternal and fetal outcomes. Further research is warranted to fully understand the therapeutic potential of this pathway and its implications for the management of hypertensive disorders in pregnancy.

## ACKNOWLEDGEMENT

None.

## CONFLICT OF INTEREST

The author has no conflicts of interest to declare.

## REFERENCES

1. Cardwell MS (2012) Pregnancy sickness: A biopsychological perspective. *Obstetr Gynecol Survey* 67(10):645-652.
2. Piwko C, Koren G, Babashov V, Vicente C, Einarson TR (2013) Economic burden of nausea and vomiting of pregnancy in the USA. *J Popul Ther Clin Pharmacol* 20(2): e149-e160.
3. Holland TD, O'Brien MJ (2003) On morning sickness and the Neolithic revolution. *Curr Anthropol* 44(5):707-711.
4. Patil CL, Abrams ET, Steinmetz AR, Young SL (2012) Appetite sensations and nausea and vomiting in pregnancy: An overview of the explanations. *Ecol Food Nutr* 51(5):394-417.
5. Pepper GV, Craig Roberts S (2006) Rates of nausea and vomiting in pregnancy and dietary characteristics across populations. *Proc R Soc Lond B Biol Sci* 273(1601):2675-2679.